Women’s Health Market Report

Women’s Health Market Analysis By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome), By Region, And Segment Forecasts, 2014 - 2025

Published: October 2017  |  110 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-634-9

Industry Insights

The global women’s health market size was valued at USD 36.5 billion in 2016 and is anticipated to grow at a CAGR of 3.9% over the forecast period. Increasing female geriatric population, unhealthy lifestyle, favorable government policies & initiatives by private organizations, along with introduction of new medicines for women are factors responsible for growth.

In addition, increase in public-private funding and grants for treatment of infertility are estimated to accelerate market growth. There are many organizations that provide funds (reimbursement) for treatment of infertility due to high costs associated with it. For instance, National Infertility Association provides between USD 2,000 and USD 16,000 for infertility medication.

U.S. women’s health market by application, 2014 - 2025 (USD Billion)

U.S. women’s health market

Application Insights

On the basis of application, the women’s health market has been segmented into postmenopausal osteoporosis, infertility, endometriosis, contraceptives, menopause, and Polycystic Ovary Syndrome.

In 2016, postmenopausal osteoporosis segment held the largest share due to increase in population of women older than 40 years and entry of new drugs to treat menopausal osteoporosis. Presence of various major players and ongoing R&D are likely to drive growth of this segment during the forecast period.

Major drugs operating in the market in 2016 were Evista, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, Forteo, Premarin, Actonel, and Ortho-Tri-Cy LO 28. The market is expected to witness patent expiration in the coming years. However, presence of a drug pipeline for women’s health and recent approvals are likely to drive the market. For instance, in May 2017, TYMLOS (abaloparatide) received FDA approval for treatment of postmenopausal women with osteoporosis in the U.S. who are at high risk of developing fractures.

Contraceptives is expected to be the fastest growing segment in the coming years due to increased awareness about family planning and technologically advanced contraceptive methods. In addition, favorable government regulations in countries such as the U.S., coupled with growing awareness about various contraceptive methods, are likely to accelerate use of contraceptives, and this is expected to boost growth of this segment.The Mirena IUD lost its initial patent in 2015 however, Bayer was able to extend their protection until 2029 by developing new inserter.

Global women’s health market by region, 2016 (%)

Global women’s health market

Regional Insights

North America held the highest share in the women’s health market in 2016. Increase in population of older women in this region is one of the key factors boosting demand for women’s health products. Nearly 15% of the female population of North America is aged above 65 years, and they experience various physiological and emotional issues owing to hormonal changes.

Furthermore, higher awareness in developed regions such as North America, high healthcare expenditure, and rise in preference for using biologics in women are some of the key factors that can be attributed to the dominance of the region.

Asia Pacific is expected to witness substantial growth during the forecast period owing to a large population base and increasing demand for contraceptives. China and India are the two most populated countries in the world. Increase in government initiatives undertaken in countries such as India, China, Sri Lanka, and Bangladesh to control population growth is expected to positively impact the women’s health market in this region.

Japan, China, India, Australia, and Singapore are major countries in Asia Pacific. As of 2016, Japan held more than 20.0% of the Asia Pacific market. In Japan, majority of the current population is above 50 years of age. Government data shows that approximately 40% of the total population is aged 65 years and above. Increase in prevalence of breast cancer, endometriosis, and postmenopausal osteoporosis is expected to drive growth.

Competitive Insights

Some of the key players operating in the women’s health market are Agile Therapeutics; Allergan; Amgen, Inc.; AstraZeneca; Bayer AG; Bristol-Myers Squibb Company; Ferring B.V.; Merck & Co., Inc.; Pfizer, Inc.; and Teva Pharmaceutical Industries Ltd. Players have been engaging in collaborations for R&D, expansion of product portfolios, and regional expansion in emerging markets to increase their market share.

Intrarosa, Addyi (flibanserin), Duavee (conjugated estrogens/bazedoxifene), and Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) are some of the products approved by U.S. FDA in the past three to four years. Entry of new products in the market due to investments by players is expected to drive growth.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, UK, China, Japan, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis on industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global women’s health market on the basis of application and region.

  • Application Outlook (Revenue, USD Million, 2014 - 2025)

    • Postmenopausal Osteoporosis

    • Infertility

    • Endometriosis

    • Contraceptives

    • Menopause

    • Polycystic Ovary Syndrome (PCOS)

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $3,450
Multi User - $6,450
Enterprise User - $8,450

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA